StreetInsider.com News Articles

Nurix (NRIX) PT Raised to $33 at Baird

Thu, 18 Jun 2026 06:14:00 -0400

Baird analyst Brian Skorney raised the price target on Nurix (NASDAQ: NRIX) to $33.00 (from $26.00) while maintaining a Outperform rating.

Stifel Reiterates Buy Rating on Nurix (NRIX)

Mon, 15 Jun 2026 09:30:03 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $34.00 price target on Nurix (NASDAQ: NRIX).

The analyst commented, "Updated P1a/b bexobrutideg data presented at EHA reinforce our best-in-class investment thesis (degrader/inhibitor agnostic) – with updated P1a dose-escalation data highlighting our confidence in bexobrutideg achieving superiority vs. pirtobrutinib in the planned P3 DAYBreak CLL-306 trial (meaningfully better data in more-difficult-to-treat patients) and preliminary P1b results (Cohorts 5/15) providing the first glimpse of safety/efficacy in earlier lines of therapy (now readily accessible via the Roche collaboration). Updated/ incremental P1a/b tacabrutideg (ONC’s BGB-16673) results further reinforce the biological/competitive advantages of degradation vs. inhibition

Form 8-K Nurix Therapeutics, Inc. For: Jun 11

Thu, 11 Jun 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260611/26632535.html

Form 8-K Nurix Therapeutics, Inc. For: Jun 11

Thu, 11 Jun 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260611/26632535.html

Nurix reports updated trial results for BTK degrader in blood cancers

Thu, 11 Jun 2026 07:01:18 -0400

Nurix Therapeutics Inc. (NASDAQ: NRIX) announced updated clinical data from its ongoing Phase 1a/b trial evaluating bexobrutideg, an investigational BTK degrader, in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The Phase 1a study enrolled 48 patients with relapsed/refractory disease who had received a median of four prior therapies. Results showed a median progression-free survival of 22.1 months and an objective response rate of 83% with a median follow-up of 22.4 months, according to the company's statement.

In earlier-line treatment cohorts from the Phase 1b portion, the company reported an objective response rate of 92.9% among 14 evaluable patients who had

Nurix reports updated trial results for BTK degrader in blood cancers

Thu, 11 Jun 2026 07:01:18 -0400

In earlier-line treatment cohorts from the Phase 1b portion, the company reported an objective response rate of 92.9% among 14 evaluable patients who had

Nurix reports updated trial results for BTK degrader in blood cancers

Thu, 11 Jun 2026 07:01:18 -0400

In earlier-line treatment cohorts from the Phase 1b portion, the company reported an objective response rate of 92.9% among 14 evaluable patients who had

Nurix reports updated trial results for BTK degrader in blood cancers

Thu, 11 Jun 2026 07:01:18 -0400

In earlier-line treatment cohorts from the Phase 1b portion, the company reported an objective response rate of 92.9% among 14 evaluable patients who had

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Thu, 11 Jun 2026 07:00:00 -0400

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment

Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients

Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures

Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement

Data to be presented at the 2026 European Hematology Association

H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)

Thu, 11 Jun 2026 06:42:48 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $32.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented: "Earlier this week, Nurix announced that it has inked a high-profile collaboration arrangement with Roche (RHHBY; not rated) for the co-development and U.S. co-commercialization of Nurix's BTK degrader, bexobrutideg. Per the agreement, the parties will co-commercialize bexobrutideg in the U.S. across all indications, and split profits and losses from U.S. commercialization equally; outside the U.S., Roche is responsible for commercialization. In exchange for these rights, Roche will pay Nurix $700M upfront, with Nurix also being eligible to receive up to $2.3B

UBS Reiterates Buy Rating on Nurix (NRIX)

Tue, 09 Jun 2026 09:30:52 -0400

UBS analyst David Dai reiterated a Buy rating and $23.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX announced a global collaboration with Roche for bexobrutideg (bexo, BTK degrader), with $700M upfront and up to $2.3B potential milestones. Both companies will co-develop bexo globally, with development costs split 40/60 (NRIX/Roche) across indications, and NRIX will retain a 50/50 U.S. profit share and receive ex-U.S. royalties. We think the deal is positive to both NRIX and Roche. It validates bexo's best-in-class potential and the market opportunity across hematology/autoimmune indications. The $700M upfront strengthens NRIX’s near-term cash position, and brings Roche’s

Nurix (NRIX) PT Raised to $32 at Truist Securities

Tue, 09 Jun 2026 07:06:13 -0400
Truist Securities analyst Greg Renza raised the price target on Nurix (NASDAQ: NRIX) to $32.00 (from $30.00) while maintaining a Buy rating.

Nurix (NRIX) PT Raised to $45 at Jefferies

Mon, 08 Jun 2026 13:21:58 -0400

Jefferies analyst Roger Song raised the price target on Nurix (NASDAQ: NRIX) to $45.00 (from $41.00) while maintaining a Buy rating.
The analyst comments "NRIX announced a global co-dev/co-com deal with Roche for bexobrutideg (BTK degrader) across heme, immunology, and neurology. Terms: $700M upfront, up to $2.3B milestones, 50/50 US profit share, 40/60 dev cost split, exUS royalties. Program spans Ph2/3 CLL plus planned Ph2 in CSU/MS. Early CLL Ph1 shows 83% ORR (n=47) and mPFS 22.1 mo. Pro forma cash ~ $1.24B. Bottom Line. We think the Roche partnership de-risks development and expands scope from CLL into a multi-indication franchise

Nurix (NRIX) PT Raised to $45 at Jefferies

Mon, 08 Jun 2026 13:21:58 -0400

Jefferies analyst Roger Song raised the price target on Nurix (NASDAQ: NRIX) to $45.00 (from $41.00) while maintaining a Buy rating.
The analyst comments "NRIX announced a global co-dev/co-com deal with Roche for bexobrutideg (BTK degrader) across heme, immunology, and neurology. Terms: $700M upfront, up to $2.3B milestones, 50/50 US profit share, 40/60 dev cost split, exUS royalties. Program spans Ph2/3 CLL plus planned Ph2 in CSU/MS. Early CLL Ph1 shows 83% ORR (n=47) and mPFS 22.1 mo. Pro forma cash ~ $1.24B. Bottom Line. We think the Roche partnership de-risks development and expands scope from CLL into a multi-indication franchise

Nurix (NRIX) PT Raised to $45 at Jefferies

Mon, 08 Jun 2026 13:21:41 -0400
Jefferies analyst Roger Song raised the price target on Nurix (NASDAQ: NRIX) to $45.00 (from $41.00) while maintaining a Buy rating.

Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'

Mon, 08 Jun 2026 10:48:43 -0400

Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix announced a global collaboration with Roche to co-develop and co-commercialize bex-deg, and in our view this is the outcome investors were hoping for. The deal includes a $700M upfront payment, up to $2.3B in total milestones, a 50/50 US profit split, and royalties on ex-US sales. The collaboration extends well beyond the ongoing DAYBreak studies, with plans for additional label-enabling studies in B-cell malignancies and Phase 2 development in multiple sclerosis and chronic spontaneous urticaria. Importantly, Roche brings deep expertise across

Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'

Mon, 08 Jun 2026 10:48:43 -0400

Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix announced a global collaboration with Roche to co-develop and co-commercialize bex-deg, and in our view this is the outcome investors were hoping for. The deal includes a $700M upfront payment, up to $2.3B in total milestones, a 50/50 US profit split, and royalties on ex-US sales. The collaboration extends well beyond the ongoing DAYBreak studies, with plans for additional label-enabling studies in B-cell malignancies and Phase 2 development in multiple sclerosis and chronic spontaneous urticaria. Importantly, Roche brings deep expertise across

Nurix (NRIX) trades up 20%, RBC says agreement with Roche removes some overhangs, 'We remain buyers'

Mon, 08 Jun 2026 09:42:45 -0400
(Updated - June 8, 2026 9:42 AM EDT)
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Overnight, NRIX and Roche announced a partnership for NRIX's lead drug bex-deg, which we believe helps address several lingering unknowns and should help position the drug - a differentiated, high-quality, and relatively de-risked Btk degrader - optimally for future success. The deal includes $700M upfront, up to $1.6M in developmental, regulatory, and commercial milestones, a 50/50 U.S. profit split, and tiered teen % royalties ex-U.S. We believe this structure makes sense, as it should